



MAMMALIAN TOXICOLOGY OF SODIUM XYLENE SULFONATE (SXS)

Applicable to these current Stepan products:

| | | |
|----------------|--|--|
| STEPANATE® SXS | | |
|----------------|--|--|

Toxicological Information:

| <u>Test/Conditions</u> | <u>Results/Classification</u> | <u>References</u> |
|--|---|-------------------------|
| Acute Oral Toxicity (rat) (14 day) (gavage)/ n = 5/dose/sex | LD ₅₀ (Lethal Dose) greater than 5g/kg (practically non-toxic orally as a 40% solution) | SDA ¹ |
| Acute Dermal Toxicity (rabbit) (14 day) | LD ₅₀ greater than 0.8g/kg (moderately toxic dermally) | SDA |
| Acute Inhalation Toxicity (rabbit) (4 hr. exposure) | LC ₅₀ (Lethal Concentration) greater than 6.41 mg/l (moderately toxic by inhalation) | SDA |
| Primary Eye Irritation (rabbit) (7 day observation) n=6 | Mildly irritating to eyes as 40% solution | SDA |
| Primary Dermal Irritation (rabbit) n=6 | Mildly irritating to skin as 40% solution | SDA |
| Subchronic Oral Toxicity (diet) (rat)(90 day) | No effects observed at 0.1% in the diet | SDA |
| Mutagenicity Study (Ames Test) | Not mutagenic | NTP Report ² |
| Carcinogenicity Study (rats/mice) (2 yr.) (dermal application) | Not a carcinogen | NTP Report |

References:

1Soap and Detergent Association (SDA) Communication Paper, May, 1982.

2National Toxicology Program (NTP) Report on the Toxicology and Carcinogenesis Studies of Technical Grade Sodium Xylene Sulfonate, 1995.

STEPANATE® is a registered trademark of Stepan Company.

Last Update: **03/23/99**

Revision Reference: **TX011.00**

Nothing contained herein grants or extends a license, express or implied, in connection with patents, issued or pending, of the manufacturer or others. The information contained herein is based on the manufacturer's own study and the works of others. The manufacturer makes no warranties, expressed or implied, as to the accuracy, completeness, or adequacy of the information contained herein. The manufacturer shall not be liable (regardless of fault) to the vendee's employees, or anyone for any direct, special or consequential damages arising out of or in connection with the accuracy, completeness, adequacy or furnishing of such information.